Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia

Erstveröffentlichung
2009
Metadata only
Search for full text

Wissenschaftlicher Artikel

Autoren
Giannopoulos, K.
Dmoszynska, A.
Kowal, M.
Wasik-Szczepanek, E.
Bojarska-Junak, A.
et al.
Institutionen
UKU. Klinik für Innere Medizin III
Erschienen in
Leukemia ; 23 (2009), 10. - S. 1771-1778. - ISSN 0887-6924
Link zur Veröffentlichung
https://dx.doi.org/10.1038/leu.2009.98
Förderinformationen
Polish Scientific Committee [N402 034 31/1138, N402 10732/3496]
Foundation for Polish Science
Schlagwörter
chronic lymphocytic leukemia (CLL); thalidomide; gene expression profiling (GEP); heavily pretreated patients; low-dose thalidomide; regulatory t-cells; oral fludarabine; genomic aberrations; multiple-myeloma; mutation status; expression; survival; combination
DDC-Sachgruppe
DDC 610 / Medicine & health
Metadata
Zur Langanzeige